Continuous antigenic stimulation system (CASS) as a new immunization strategy

Andrew Gomez-Vargas, Kenneth L. Rosenthal, Mark R. McDermott, Gonzalo Hortelano

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Protection against diseases is mediated by a sustained immune response. Here, we describe a new immunization strategy. Mice implanted with encapsulated C2C12 myoblasts secreting human factor IX (hFIX) elicited a strong humoral response against the transgene, as compared to mice immunized with complete Freund's adjuvant (FA). Mice also had increasing IgG2a antibody titer, indicating a switch to a Th1 profile immune response. Mice developed strong hFIX-specific cytotoxic T lymphocytes (CTL) that was detectable 213 days after implantation, demonstrating the sustained immunity elicited by encapsulated cells. Here, we propose continuous antigenic stimulation system (CASS) as a novel immunization strategy with potential application in the design of novel vaccines.

Original languageEnglish
Pages (from-to)3902-3910
Number of pages9
Issue number29-30
Publication statusPublished - Sep 28 2004


  • Antigen stimulation system
  • Immune response
  • Immunization strategy

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Continuous antigenic stimulation system (CASS) as a new immunization strategy'. Together they form a unique fingerprint.

Cite this